Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/25/2009

nses related to ANX-514 and a $0.1 million increase in personnel costs, offset by a $1.6 million decrease in external clinical trial expenses related to ANX-510, or CoFactor(R), and ANX-530 and a $0.2 million decrease in non-cash, stock-based compensation expenses. R&D expenses for the three-month period ended December 31, 2008 included non-cash, stock-based compensation expenses amounting to $0.1 million compared to $0.3 million for the same period a year ago.

Selling, general and administrative, or SG&A, expenses increased by $0.8 million, or 40%, to $2.6 million for the three-month period ended December 31, 2008, from $1.9 million for the same period a year ago. The increase was substantially due to a $0.6 million increase in severance expenses, a $0.2 million increase for consulting expenses related to market research and a $0.1 million increase in professional services, offset by a $0.1 million decrease in non-cash, stock-based compensation expenses. SG&A expenses for the three-month period ended December 31, 2008 included non-cash, stock-based compensation expenses amounting to $0.1 million, compared to $0.3 million for the same period a year ago.

Interest income amounted to $18,000 for the three-month period ended December 31, 2008, compared to $438,000 for the same period a year ago. The decrease in interest income was primarily attributable to lower invested balances and interest rates.

Year 2008 Operating Results

ADVENTRX's net loss was $26.6 million, or $0.30 per share, for 2008, compared to a net loss of $22.1 million, or $0.25 per share, for 2007. Included in the loss for 2008 were non-cash, share-based compensation expenses amounting to $1.6 million compared to $2.5 million for the same period in 2007.

R&D expenses increased by $2.0 million, or 12%, to $17.9 million for 2008, from $15.9 million for 2007. The increase was primarily due to a $6.2 mil
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Further Cost-Cutting Measures
2. ADVENTRX Provides Update on Strategic Transaction Process
3. ADVENTRX Announces Further Cost-Cutting Measures
4. ADVENTRX Exploring Strategic Options
5. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
7. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. ADVENTRX Settles Dispute With Former Licensee
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. ADVENTRX Appoints Vice President of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market for ... billion in 2013. This is estimated to grow to ... growth rate (CAGR) of 28.6%. , New digital PCR ... possibilities within the broader PCR field. The opportunities presented ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... independent, predictor of heart attack and stroke ... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a worldwide developer ... be exhibiting its,AspirinWorks(R) Test November 9 - 11 in ... 2008 in New Orleans, La., New CHARISMA trial ...
... EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: ... today,announced that Mr. Kevin Giese, President and CEO, will present ... York., WHEN: Monday November ... New York Palace Hotel, New York., About BioMS Medical ...
... Calif., Nov. 5 Neurobiological,Technologies, Inc. (Nasdaq: NTII ... Executive Officer, will present at the Rodman & Renshaw,10th ... New York Palace,Hotel., Mr. Freiman,s presentation will take ... presentation will be webcast and can be accessed by ...
Cached Biology Technology:Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting 2Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting 3BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference 2
(Date:7/11/2014)... the proteins that let nerve cells send out electrical ... a biological tactic that may offer a new way ... and environmentally responsible way. , Their findingthat naturally ... and harmless for a closely related onesuggests that insecticides ... beneficial species like bees. A summary of the research, ...
(Date:7/10/2014)... Mass. , June 30, 2014  Aware, Inc. ... biometrics software and services, previously announced on June 26, ... special cash dividend of $1.75 per share, or approximately ... date of July 10, 2014 and a payment date ... by NASDAQ that it had set an ex-dividend date ...
(Date:7/10/2014)... -- According to the new market research ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... Finance), and Geography - Global Trends & Forecasts to ... Sensors Market is projected to cross $14.35 Billion by ... 2014 to 2020. Browse more than 78 ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... with colleagues in Sweden and abroad, have identified an entirely ... inhibits formation of new blood vessels. Inhibiting the formation of ... cancer treatment. The study is published in the November issue ... the formation of new blood vessels, is strictly regulated by ...
... the number of weeks of pregnancy, due to associated problems ... brain damage can result. The condition, known as Intra-uterine ... a baby,s health and determine the best time for delivery. ... had to rely on educated guesses about the strength of ...
... MADISON, WI, NOVEMBER 9, 2009 -- Agricultural ... a result of their presence in wastes (sewage biosolids ... periods of time. Regulations and guidelines for tolerable concentrations ... on the assumption that the toxic effects of the ...
Cached Biology News:New mechanism explains how the body prevents formation of blood vessels 2Healthy babies by the numbers 2Additive copper-zinc interaction affects toxic response in soybean 2
MpV17 transgene, murine homolog, glomerulosclerosis...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and ...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
Biology Products: